John Byrd

Dec 9, 2024 | streetinsider.com | John Byrd

Tweet Share E-mail0 shares, /PRNewswire/ -- Lomond Therapeutics, a spin-out of Eilean Therapeutics LLC, a precision oncology-focused discovery and development platform, today announced results from single ascending dose Phase 1 clinical studies of oral once-daily lonitoclax. In this series of healthy volunteer studies, no significant safety signals were observed at exposures where robust inhibition of BCL-2 was achieved, as measured via ex vivo activation of caspase in CLL primary cells.

Dec 6, 2024 | lymphomahub.com | John Byrd

All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition. The Lymphoma Hub uses cookies on this website. They help us give you the best online experience.

Nov 11, 2024 | morningstar.com | John Byrd

LOMOND THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE ASH ANNUAL MEETINGPR NewswireDOVER, Del., Nov. 11, 2024DOVER, Del., Nov.

Nov 4, 2024 | streetinsider.com | John Byrd

1. AMZN2. AAPL3. INTC4. TEAM5. RBLX6. EL7. BA8. COHU9. REGN10. STM Tweet Share E-mail0 shares, /PRNewswire/ -- Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, today announced the completion of a reverse merger transaction with Venetian-1 Acquisition Corp. and the closing of a $44 million private placement financing.

Oct 29, 2024 | streetinsider.com | John Byrd

, /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company targeting escape mutations in hematologic and solid malignancies, today announced that an abstract related to the company's first-in-class oral MALT1 degrader has been accepted for a poster presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held from December 7-10, 2024 in San Diego.